Ask AI
Back Back
ProCE Banner Activity

Addressing Treatment Needs in ADH1: Patient Perspectives and Expert Insights

Clinical Thought

In this ClinicalThought, explore the diagnosis and management of autosomal dominant hypocalcemia type 1 (ADH1) through patient experiences and expert viewpoints. Learners will examine clinical features that prompt suspicion for ADH1, the roles of genetic testing and family screening in establishing a definitive diagnosis, and current and emerging therapeutic strategies that address limitations of conventional treatment while improving long-term disease management and patient outcomes.

Released: July 29, 2026

Continue Activity View Activity

Share

Faculty

Geena DellaFiore

Geena DellaFiore

Patient diagnosed with ADH1
Michael Mannstadt

Michael Mannstadt, MD

Chief, Endocrine Unit
Associate Professor in Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts
Mark L. Warren

Mark L. Warren, MD, FACE

Director of Clinical Trials and Director of Laboratory Services
Physicians East Private Practice
Assistant Professor of Medicine
Campbell University School of Osteopathic Medicine
Lillington, North Carolina

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with HypoPARAthyroidism Association, Inc.

ProCE Banner

Supporters

This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Partners

HypoPARAthyroidism Association, Inc

ProCE Banner

Target Audience

This activity is designed for clinicians involved in the management of patients with ADH1, including endocrinologists, nephrologists, primary care physicians, orthopedists, nurse practitioners, physician associates, and other members of the care team. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify ADH1 as an underrecognized cause of hypoparathyroidism by recognizing clinical features that raise suspicion for the diagnosis

  • Understand the activating mutations in the calcium-sensing receptor (CaSR) gene that underlie ADH1

  • Apply genetic testing strategies for suspected ADH1, including appropriate test selection, result interpretation, and consideration of access and ethical implications, to confirm diagnosis and inform clinical management

  • Evaluate emerging clinical trial evidence for novel therapeutic approaches that target the underlying causes of ADH1, including CaSR-targeted therapies, to optimize calcium homeostasis and reduce renal complications

Financial Disclosures

Primary Author

Geena DellaFiore has no relevant financial relationships to disclose.

Michael Mannstadt, MD: consultant/advisor/speaker/researcher: Amolyt/Alexion, BridgeBio, Takeda.

Mark L. Warren, MD, FACE, has no relevant financial relationships to disclose.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.